Serum iron levels as a new biomarker in chemotherapy with leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan, with or without molecularly-targeted drugs
Serum iron levels have been reported to increase following the administration of various anticancer drugs. An increase in serum iron levels during therapy with leucovorin and fluorouracil plus oxaliplatin (FOLFOX) or leucovorin and fluorouracil plus irinotecan (FOLFIRI) was also observed. The aim of...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
D.A. Spandidos
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916199/ |